[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Myriad Genetics Inc (MYGN)

Myriad Genetics Inc (MYGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Myriad Genetics: The Streak of Missing Estimates Puts Management Credibility on the Line

Myriad Genetics Inc (MYGN) reports second-quarter fiscal 2026 earnings after the close on July 30, 2026, with analysts expecting a loss of $0.08 per share. The molecular diagnostics company faces a critical test as it attempts to reverse a pattern of inconsistent profitability while navigating a challenging operating environment. With the stock trading at $5.05 and analyst sentiment mixed, investors will be watching closely for signs of sustainable improvement in the company's core genetic testing business.

Myriad Genetics is a molecular diagnostic company specializing in genetic testing and precision medicine, with a focus on oncology, women's health, and mental health applications. The company's revenue streams...

Fundamentals

See More
  • Market Capitalization, $K 476,018
  • Shares Outstanding, K 94,448
  • Annual Sales, $ 824,500 K
  • Annual Income, $ -365,900 K
  • EBIT $ -64 M
  • EBITDA $ 309 M
  • 60-Month Beta 1.64
  • Price/Sales 0.61
  • Price/Cash Flow 1.41
  • Price/Book 1.49

Options Overview Details

View History
  • Implied Volatility 99.26% (-20.89%)
  • Historical Volatility 60.97%
  • IV Percentile 21%
  • IV Rank 8.68%
  • IV High 586.89% on 02/19/26
  • IV Low 52.89% on 08/12/25
  • Expected Move (DTE 22) 1.33 (25.50%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 626
  • Volume Avg (30-Day) 88
  • Put/Call OI Ratio 0.22
  • Today's Open Interest 2,362
  • Open Int (30-Day) 2,213
  • Expected Range 3.87 to 6.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.08
  • Number of Estimates 1
  • High Estimate $-0.08
  • Low Estimate $-0.08
  • Prior Year $-0.06
  • Growth Rate Est. (year over year) -33.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.03 +3.98%
on 07/30/26
6.43 -18.66%
on 07/16/26
-0.48 (-8.41%)
since 06/30/26
3-Month
3.53 +48.16%
on 05/19/26
6.43 -18.66%
on 07/16/26
+0.48 (+10.11%)
since 04/30/26
52-Week
3.53 +48.16%
on 05/19/26
8.59 -39.12%
on 10/16/25
+1.18 (+29.14%)
since 07/30/25

Most Recent Stories

More News
Myriad Genetics: The Streak of Missing Estimates Puts Management Credibility on the Line

Barchart Research What to Expect from MYGN Earnings MYGN Generated July 29, 2026 Current Price $5.05 EPS Estimate $$-0.08 Consensus Rating Hold Average Move 18.01% Myriad Genetics: The Streak of Missing...

MYGN : 5.26 (+4.37%)
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings

Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings

MYGN : 5.26 (+4.37%)
3 Unprofitable Stocks That Fall Short

3 Unprofitable Stocks That Fall Short

MYGN : 5.26 (+4.37%)
BAX : 26.21 (+5.81%)
PRPL : 7.42 (-6.43%)
Myriad Genetics to Release Second Quarter 2026 Financial Results on July 30, 2026

SALT LAKE CITY, July 23, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. , (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its second quarter 2026 earnings...

MYGN : 5.26 (+4.37%)
3 Reasons MYGN is Risky and 1 Stock to Buy Instead

3 Reasons MYGN is Risky and 1 Stock to Buy Instead

MYGN : 5.26 (+4.37%)
Myriad Genetics Launches FirstGene® Multiple Prenatal Screen

SALT LAKE CITY, July 21, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces the full commercial launch of...

MYGN : 5.26 (+4.37%)
New Large-Scale Meta-Analysis Demonstrates Strong Prognostic Performance of Myriad’s Prolaris® Biopsy Test in Localized Prostate Cancer

SALT LAKE CITY, July 02, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces newly published data from the...

MYGN : 5.26 (+4.37%)
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

1 Unpopular Stock That Should Get More Attention and 2 We Find Risky

KO : 88.33 (-0.84%)
RH : 165.52 (-6.03%)
MYGN : 5.26 (+4.37%)
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1

MYGN : 5.26 (+4.37%)
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today

Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today

MYGN : 5.26 (+4.37%)

Business Summary

Myriad Genetics employs a number of proprietary technologies to target the genetic basis of human diseases and the role these genes might play in the onset, progression and treatment of the respective diseases. The company has more than 10 proprietary molecular diagnostic products in market. It has made...

See More

Key Turning Points

3rd Resistance Point 5.70
2nd Resistance Point 5.57
1st Resistance Point 5.30
Last Price 5.26
1st Support Level 4.90
2nd Support Level 4.77
3rd Support Level 4.50

See More

52-Week High 8.59
Fibonacci 61.8% 6.66
Fibonacci 50% 6.06
Fibonacci 38.2% 5.46
Last Price 5.26
52-Week Low 3.53

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.